Delfi Diagnostics is developing algorithms to detect cancer-derived DNA in blood. To detect cancer early, innovative diagnostics need to be developed. Delfi is exploiting detectable cell-free DNA derived from cancer cells. Delfi analyzes DNA in blood by sequencing and using artificial intelligence to identify unique fragmentation patterns that signal cancer presence. Focusing on DNA fragments rather than cancer-associated mutations enables accurate cancer detection from a single blood sample. Millions of data points are used to diagnose both cancer presence and the tissue of origin. Delfi is putting its technology to the test in a ground-breaking clinical trial, CASCADE-LUNG, to detect lung cancer in individuals at risk who currently do not have cancer.